食物ワクチン市場：タイプ別、用途別、地域別、2026-2032年

食物ワクチン市場の評価-2026-2032年

特に発展途上地域において、代替ワクチン接種方法に対する需要が高まっていることから、食物ワクチンへの関心が高まっています。感染症の有病率の増加と予防医療への関心の高まりが、この分野への研究投資と技術革新を後押ししています。食物ワクチンのニーズは、2023年には83億5,000万米ドルを超え、2032年には129億1,000万米ドルに達します。

さらに、ワクチンを生産するための作物の遺伝子組換えを可能にする植物バイオテクノロジーの進歩が、食物ワクチンの実現可能性を高めています。食物ワクチンの費用対効果、保存の容易さ、輸送のしやすさは、世界の予防接種の取り組みにおける重要な課題に対処するものであるため、市場の拡大をさらに後押ししています。これらの要因により、様々な産業で食物ワクチンの使用が増加しており、2026年から2032年までのCAGRは6.18%で成長すると予想されます。

食物ワクチン市場定義/概要

食物ワクチンは、抗原を産生する遺伝子組換え作物や植物であり、摂取することで免疫反応を刺激し、針を使わず簡単に投与できるワクチン接種法を提供します。主な用途には、B型肝炎、コレラ、狂犬病などの感染症対策があり、従来のワクチン接種では物流やアクセスの面で障壁がありました。将来的には、食物ワクチンは、コールドチェーンへの依存や製造コストを削減できるため、特に低資源環境において、広範で費用対効果の高い予防接種の可能性を秘めています。植物バイオテクノロジーの開発と予防医療への関心の高まりが今後の発展を促し、食物ワクチンを世界の公衆衛生イニシアチブの有望なツールとすることが期待されます。

予防医療への意識の高まりは食物ワクチン市場を促進するか？

予防医療に対する意識の高まりが、食物ワクチン市場を大きく後押ししています。人々の予防衛生に対する意識が高まるにつれ、病気と闘うための積極的な対策へのシフトが見られ、食物ワクチンのような革新的なワクチン接種ソリューションへの関心が高まっています。世界保健機関（WHO）は、ワクチンで予防可能な病気によって毎年約150万人が死亡していると指摘し、効果的な予防接種戦略の必要性を強調しています。米国では、疾病対策予防センター（CDC）の報告によると、予防接種に対する意識が高まる傾向にあり、ポリオや麻疹などの病気に対する子どもの予防接種率は95％近くに達しています。

特に医療インフラが限られている地域では、利用しやすく非侵襲的なワクチンソリューションに対するこのような需要が、食物ワクチンの利点と一致し、市場をさらに活性化させています。さらに、食物ワクチンは、ワクチン接種における重要なロジスティクスの課題に対する解決策を提供します。従来のワクチンとは異なり、冷蔵を必要としないため、一貫したコールドチェーンのインフラがない地域に特に適しています。国連の報告書によると、低所得国の30％以上がコールドチェーン不足に直面しており、効果的な予防接種の普及に影響を及ぼしています。食物ワクチンは、少ない資源で現地生産・流通が可能であるため、こうした課題を解決するのに役立ちます。

コスト高とアクセシビリティは食物ワクチン市場の成長を妨げるか？

高いコストと入手しやすさの課題は、食物ワクチン市場の成長を妨げる可能性があります。食物ワクチンの開発には、高度な遺伝子工学、厳格な臨床試験、規制当局の承認が必要であり、これらすべてが製造コストに上乗せされます。これらの費用は、特に、従来のワクチンが政府プログラムや国際機関から助成を受けていることが多い低・中所得国において、購入可能な価格に制限を与える可能性があります。このような高コスト構造は、特に資金が限られている地域では、採用率を鈍らせる可能性があります。

さらに、遺伝子組換え作物の大規模栽培や流通のためのインフラがどこでも利用できるとは限らないため、アクセシビリティにも懸念が残る。欧州のような地域では、遺伝子組換え作物（GMO）を管理する厳しい規制の枠組みも障害となっており、食物ワクチンの展開が制限される可能性があります。その結果、食物ワクチンには有望な利点がある一方で、高いコストと入手のしやすさの制限が、その普及に大きな課題となっています。

目次

第1章 食物ワクチンの世界市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 食物ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 食物ワクチンの世界市場：用途別

• 概要
• 家畜
• 医療

第6章 食物ワクチンの世界市場：タイプ別

• 概要
• 不活化ワクチン
• その他

第7章 食物ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の食物ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• GlaxoSmithKline
• Sanofi S.A.
• Merck & Co., Inc.
• Ceva
• Santa Cruz Animal Health
• Merial

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Edible Vaccine Market Valuation - 2026-2032

The rising demand for alternative vaccination methods, particularly in developing regions, is propelling interest in edible vaccines as they offer an easier, needle-free delivery mechanism that enhances accessibility and compliance. Increasing prevalence of infectious diseases and growing focus on preventive healthcare are encouraging research investments and innovation in this field. The need for edible vaccine is surpassing USD 8.35 Billion in 2023 and reaching USD 12.91 Billion by 2032.

Additionally, advances in plant biotechnology, which enable the genetic modification of crops to produce vaccines, have strengthened the feasibility of edible vaccines. The cost-effectiveness, ease of storage, and transport of edible vaccines further fuel market expansion as these factors address critical challenges in global immunization efforts. These factors contribute to the increasing use of edible vaccine in a variety of industries is expected to grow at a CAGR of 6.18% about from 2026 to 2032.

Edible Vaccine Market: Definition/ Overview

Edible vaccines are genetically engineered crops or plants that produce antigens, stimulating an immune response when consumed, offering a needle-free, easily administered vaccination method. Their primary applications include combating infectious diseases like hepatitis B, cholera, and rabies, where traditional vaccination faces logistical or accessibility barriers. Looking ahead, edible vaccines hold potential for widespread, cost-effective immunization, especially in low-resource settings, as they reduce cold-chain dependency and production costs. Advances in plant biotechnology and growing interest in preventive health are expected to drive future developments, making edible vaccines a promising tool for global public health initiatives.

Will Growing Awareness of Preventive Healthcare is Propelling the Edible Vaccine Market?

Growing awareness of preventive healthcare is significantly propelling the Edible Vaccine Market. As populations become increasingly conscious of preventive health, there is a shift towards proactive measures in combating diseases, boosting interest in innovative vaccination solutions like edible vaccines. The World Health Organization (WHO) notes that vaccine-preventable diseases cause approximately 1.5 million deaths each year, emphasizing the need for effective immunization strategies. In the United States, the Centers for Disease Control and Prevention (CDC) reports a rising trend in vaccination awareness, with vaccination coverage among children reaching nearly 95% for diseases like polio and measles, showcasing the population's inclination toward preventive healthcare.

This demand for accessible, non-invasive vaccine solutions, particularly in regions with limited healthcare infrastructure, aligns with the benefits of edible vaccines, further fueling the market. Additionally, edible vaccines offer solutions to critical logistical challenges in vaccination. Unlike traditional vaccines, they don't require refrigeration, making them especially suitable for areas without consistent cold-chain infrastructure. According to a United Nations report, over 30% of low-income countries face cold chain shortages, which impact effective immunization coverage. Edible vaccines can help address these challenges, as they can be produced and distributed locally with fewer resources.

Will High Costs and Accessibility Hamper the Growth of the Edible Vaccine Market?

High costs and accessibility challenges could hamper the growth of the Edible Vaccine Market. Developing edible vaccines requires advanced genetic engineering, rigorous clinical trials, and regulatory approvals, all of which add to production costs. These expenses may limit affordability, especially in low- and middle-income countries where traditional vaccines are often subsidized by government programs or international organizations. This high-cost structure could slow adoption rates, particularly in regions where funding is limited.

Moreover, accessibility remains a concern as infrastructure for large-scale cultivation and distribution of genetically engineered crops may not be available everywhere. Strict regulatory frameworks governing genetically modified organisms (GMOs) in regions like Europe also present obstacles, potentially restricting edible vaccine deployment. As a result, while edible vaccines offer promising benefits, high costs and accessibility limitations pose significant challenges to their widespread adoption.

Category-Wise Acumens

Will Widespread Usage for Inactivated Vaccine Boost the Edible Vaccine Market?

The widespread usage of inactivated vaccines can indirectly boost the Edible Vaccine Market. Inactivated vaccines are well-regarded for their safety and effectiveness, fostering trust in vaccine-based preventive healthcare. This acceptance creates a favorable environment for innovative vaccines like edible vaccines, as the public becomes more open to varied vaccination methods. As awareness of different vaccine types grows, so does the interest in more accessible, needle-free alternatives, which could drive adoption of edible vaccines, especially in communities with high demand for convenient immunization options.

Furthermore, as inactivated vaccines require careful storage and distribution, edible vaccines offer an appealing alternative in areas where cold-chain logistics are challenging. Since edible vaccines can be produced in plants, they eliminate the need for cold storage and complex distribution, addressing critical barriers associated with inactivated vaccines in low-resource settings. This added advantage could position edible vaccines as a complementary solution, further enhancing the market's growth potential.

The "Others" segment, which includes newer vaccine technologies like mRNA and viral vector vaccines, is the fastest-growing.

Will Comprehensive Ability to Provide Medical Care Fuel the Edible Vaccine Market?

The comprehensive ability of edible vaccines to enhance medical care can fuel market growth. Edible vaccines offer a promising, needle-free alternative to traditional vaccines, making immunization more accessible, especially in regions with limited healthcare infrastructure. This ability to simplify vaccine administration aligns with public health goals for increased vaccination coverage, particularly in areas where medical resources and trained personnel are scarce.

Additionally, edible vaccines reduce logistical challenges associated with cold-chain storage and distribution. As they can be produced and stored with minimal refrigeration needs, edible vaccines lower costs and improve reach in remote and underserved areas. This ease of distribution and storage supports broader healthcare initiatives, making edible vaccines an attractive option to expand medical care capabilities globally, further driving their market potential.

The Livestock segment is the fastest-growing, fueled by increasing demand for efficient, cost-effective solutions to manage animal diseases in agriculture.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Expansion of The Edible Vaccine Market?

The advanced healthcare infrastructure in North America is likely to drive the expansion of the Edible Vaccine Market. With highly developed research facilities, the region is well-positioned to support innovation in vaccine delivery systems like edible vaccines, addressing the need for easier, needle-free alternatives. The United States, in particular, invests significantly in healthcare, with federal research funding for the National Institutes of Health (NIH) reaching approximately $47.5 billion in 2022, part of which supports vaccine research and development. This robust investment landscape accelerates breakthroughs in biotechnology, supporting edible vaccine advancements.

Furthermore, high vaccination rates and supportive regulatory frameworks in North America create a favorable environment for introducing novel vaccine types. For example, in 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that approximately 72% of the population had received full COVID-19 vaccinations, showing widespread vaccine adoption and an openness to innovative health solutions. As demand for effective, accessible, and affordable vaccination options grows, edible vaccines are positioned to benefit from the region's sophisticated healthcare infrastructure and regulatory support, potentially leading to their expanded use in public health initiatives.

Will Rapid Economic Growth in Asia Pacific Propel the Edible Vaccine Market?

Rapid economic growth in the Asia-Pacific region is likely to propel the Edible Vaccine Market, primarily due to increased investment in healthcare infrastructure and a heightened focus on preventive health measures. As nations such as China and India continue to experience robust economic expansion, the demand for innovative healthcare solutions, including edible vaccines, is expected to rise significantly. According to the Asian Development Bank, the region's economy is projected to grow by approximately 5.5% in 2024, which will likely lead to increased government spending on health initiatives and improved access to vaccination programs.

Furthermore, the Asia-Pacific region faces a high burden of infectious diseases, which underscores the need for accessible vaccination solutions. The World Health Organization reported that vaccine-preventable diseases caused over 1.5 million deaths annually in low- and middle-income countries, many of which are located in this region. As governments aim to enhance immunization coverage, edible vaccines offer a viable alternative to traditional methods, facilitating easier distribution and administration. The combination of economic growth and an urgent health mandate creates a favorable environment for the Edible Vaccine Market to thrive in the Asia-Pacific region.

Competitive Landscape

The competitive landscape of the Edible Vaccine Market is characterized by rapid technological advancements and increasing innovation in diagnostic tools. Companies are focusing on developing more accurate, non-invasive, and user-friendly testing solutions to meet the growing demand for personalized and preventive healthcare. Strategic collaborations, mergers, and acquisitions are also common as firms aim to enhance their market presence and expand their product offerings.

Some of the prominent players operating in the Edible Vaccine Market include:

GlaxoSmithKline, Sanofi S.A., Merck & Co., Inc., Ceva, Santa Cruz Animal Health, Merial.

Latest Developments

In August 2024 A research team at the University of California developed an innovative oral vaccine using genetically modified edible plants. This new approach allows for easy administration without needles, potentially increasing vaccination rates. Early studies showed promising immune responses in animal models, indicating that this method could revolutionize how vaccines are delivered, particularly in underserved regions.

In July 2024 Syngenta announced a partnership with BioNTech to explore the development of edible vaccines using genetically engineered crops. This collaboration aims to leverage BioNTech's mRNA technology to create plants that can produce antigens for various diseases. The initiative could significantly reduce production costs and facilitate wider distribution of vaccines in developing countries.

In June 2024 the Food and Drug Administration (FDA) approved the first edible vaccine for rotavirus, developed by a biotechnology firm in collaboration with agricultural scientists. This landmark decision paves the way for future approvals of edible vaccines, highlighting a growing acceptance of plant-based vaccine technology. The vaccine is expected to be available in various food products, making it more accessible, especially for children in low-income countries.

Edible Vaccine Market, By Category

• Type:
• Inactivated Vaccines
• Others
• Application:
• Livestock
• Medical Care
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EDIBLE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL EDIBLE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL EDIBLE VACCINE MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Livestock
• 5.3 Medical Care

6 GLOBAL EDIBLE VACCINE MARKET, BY TYPE

• 6.1 Overview
• 6.2 Inactivated Vaccines
• 6.3 Others

7 GLOBAL EDIBLE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL EDIBLE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Sanofi S.A.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Merck & Co., Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Ceva
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Santa Cruz Animal Health
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Merial
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research